[go: up one dir, main page]

EA200800786A1 - Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем - Google Patents

Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем

Info

Publication number
EA200800786A1
EA200800786A1 EA200800786A EA200800786A EA200800786A1 EA 200800786 A1 EA200800786 A1 EA 200800786A1 EA 200800786 A EA200800786 A EA 200800786A EA 200800786 A EA200800786 A EA 200800786A EA 200800786 A1 EA200800786 A1 EA 200800786A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igf
derivatives
tetragidrobenzoazepinovye
deactivation
standardization
Prior art date
Application number
EA200800786A
Other languages
English (en)
Inventor
Ян Гунцингер
Курт Леандер
Original Assignee
Аналитикон С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аналитикон С.А. filed Critical Аналитикон С.А.
Publication of EA200800786A1 publication Critical patent/EA200800786A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Синтезированы соединения формулы (I). Обнаружено, что они регулируют понижающим образом или ингибируют экспрессию или функцию рецептора IGF-1.
EA200800786A 2005-09-09 2006-09-08 Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем EA200800786A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71517005P 2005-09-09 2005-09-09
IB2005002667 2005-09-09
PCT/IB2006/002474 WO2007029107A1 (en) 2005-09-09 2006-09-08 Isoquinolines derivatives as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
EA200800786A1 true EA200800786A1 (ru) 2008-08-29

Family

ID=37460368

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800786A EA200800786A1 (ru) 2005-09-09 2006-09-08 Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем

Country Status (10)

Country Link
US (1) US20090099133A1 (ru)
EP (1) EP1940796A1 (ru)
JP (1) JP2009507820A (ru)
KR (1) KR20080065591A (ru)
AU (1) AU2006288847A1 (ru)
BR (1) BRPI0616731A2 (ru)
CA (1) CA2621820A1 (ru)
EA (1) EA200800786A1 (ru)
NO (1) NO20081206L (ru)
WO (1) WO2007029107A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012143879A1 (en) * 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
ES2713438T3 (es) 2014-02-24 2019-05-21 Ventana Med Syst Inc Amplificación de señal de análogos de quinona metidas
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
CA2555745C (en) * 2004-03-12 2011-05-31 Analytecon S.A. Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors

Also Published As

Publication number Publication date
KR20080065591A (ko) 2008-07-14
CA2621820A1 (en) 2007-03-15
NO20081206L (no) 2008-05-29
BRPI0616731A2 (pt) 2016-08-23
JP2009507820A (ja) 2009-02-26
AU2006288847A1 (en) 2007-03-15
WO2007029107A1 (en) 2007-03-15
EP1940796A1 (en) 2008-07-09
US20090099133A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
UY29479A1 (es) Inhibidores de adn-pk
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
ATE479687T1 (de) Kinaseinhibitoren
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
ATE508119T1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
MY146989A (en) Kinase inhibitors
DK2270008T3 (da) 8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-oner som PI-3-kinaseinhibitorer
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
NO20081160L (no) Benzimidazoltiofen forbindelser
SG163585A1 (en) Melanocortin receptor ligands
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
BRPI0606379A2 (pt) triazolftalazinas
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
EA200800786A1 (ru) Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем
BRPI0407841A (pt) inibidores heterocìclicos de quinase
NO20082105L (no) Pyrazoloisokinolinderivater
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора